Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Steven M Lipkin · WEILL MEDICAL COLL OF CORNELL UNIV · 2023 · $440,288 — PROJECT SUMMARY Computerized chest tomography (CT) lung cancer screening programs have increased the detection of premalignant non-solid (NS) nodules that harbor preinvasive or minimally invasive adenocarcinoma. Given that NS nodules can progress to invasive adenocarcinoma (solid nodules), interce…
CATHERINE MARY O'CONNELL · UNIV OF NORTH CAROLINA CHAPEL HILL · 2023 · $839,721 — In a subset of Chlamydia trachomatis-infected women, the infection escapes immune control and ascends to the upper reproductive tract. There is a fundamental gap in understanding how pathways activated by chlamydial infection lead to immune pathology and reproductive morbidity in women. Its continue…
Leonidas Stamatatos · FRED HUTCHINSON CANCER CENTER · 2023 · $1,076,473 — ABSTRACT PROJECT ONE We have reported on the design of a germline-targeting recombinant (rec) HIV-1 Env-derived immunogen, 426c.Mod.Core-C4b, that activates naïve B cells that express germline VRC01-class BCRs and on “booster” rec protein immunogen, HxB2.WT.Core-C4b, that improves the maturation of …
RUTH R MONTGOMERY · YALE UNIVERSITY · 2023 · $531,460 — Abstract We propose single-cell technologies to quantify multiparameter immune markers that provide in- depth single-cell data for analysis of immune responses to vaccination in our study cohorts. The shared platforms in this service core provide efficient and reproducible profiling in support of ou…
Joseph Paul Zackular · UNIVERSITY OF PENNSYLVANIA · 2023 · $416,304 — SUMMARY - PROJECT 2 (ANTIGEN DISCOVERY) Clostridium difficile is a spore-forming pathogen that causes a wide range of gastrointestinal (GI) disorders varying in severity from mild diarrhea to fulminant colitis and death. Difficulties in treating infections with conventional antibiotics and increasin…
Deborah H. Fuller · NORTHERN ARIZONA UNIVERSITY · 2023 · $384,249 — SUMMARY Coccidioidomycosis, also known as Valley Fever (VF) impacts residents in arid regions of the world including southwestern US, areas in South and Central America and in Mexico. Annual incidences are rising overall with estimated increases in recent years of more than 200% in some areas. In ad…
CHIUNG-YU HUNG · UNIVERSITY OF TEXAS SAN ANTONIO · 2023 · $395,776 — Project Summary An estimated 350,000 people in the United States become infected with Coccidioides annually. There is an unmet need to develop better chemotherapies and a vaccine for active immunization and/or immunotherapy against coccidioidomycosis (CM). We have previously created a recombinant ch…
Brent W Segelke · LAWRENCE LIVERMORE NATIONAL SECURITY, LLC · 2023 · $162,254 — PROJECT SUMMARY/ABSTRACT Project Title: Scientific Core 2: Protein Expression and Characterization Core We will establish and operate a protein expression and characterization core that serves the Cooperative Research Center for Nano-Scaffold Vaccines Against Chlamydia trachomatis (Ct) by providing …
KENTNER SINGLETON · TENDEL THERAPIES INC. · 2023 · $599,980 — The project is focused on progressing BiTar-s3, a vaccine adjuvant agent. The project will develop a vaccine that targets HA stem epitopes shared across many flu-A strains, thereby addressing the difficulty of eliciting heterosubtypic neutralizing antibodies (nAb) against influenza. Specifically, th…
WENDELL BERES · DUKE UNIVERSITY · 2023 · $6,174,301 — Preclinical and Translational Vaccine Development for HIV and Other Candidate Agents (PTVDS): This program will provide NIAID with a broad and flexible range of capabilities that are required for preclinical and translational development support for promising vaccines and related products for HIV an…
JOSEPH M FOX · UNIVERSITY OF DELAWARE · 2023 · $256,851 — Project Summary The goal of this Center of Biomedical Research Excellence is to continue our efforts to develop molecular approaches for probing biology, to discover and apply new chemical biology tools for the study of biological pathways associated with disease, and to develop computational approa…
David A. Hafler · YALE UNIVERSITY · 2023 · $2,706,289 — ABSTRACT We propose a deep interrogation and a systems approach that will identify molecular signatures to vaccination across three cohorts of vulnerable patient populations: autoimmune patients with B cell depletion, aged and frail individuals, and patients with sickle cell disease who are functio…
Mehul Shamal Suthar · EMORY UNIVERSITY · 2023 · $754,544 — Humoral immunity is an essential component of the immune response to flavivirus infection. Primary infection generates a robust neutralizing antibody response that mediates viral control and protection. It is becoming increasingly apparent that secondary infection with a closely related flavivirus s…
Jacob Brenner · UNIVERSITY OF PENNSYLVANIA · 2023 · $679,571 — ABSTRACT / PROJECT SUMMARY Despite 50+ years of dissecting the pathways of acute respiratory distress syndrome (ARDS), there are still no drugs which improve its mortality. From a pharmacology perspective, this lack of clinical trial success falls into 2 major buckets: poor drug delivery to the alv…
Yuan Shi · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2023 · $390,000 — Project Summary Influenza A virus causes disease in 5-20% of the population with over 200,000 hospitalizations annually in US. The antigen drift and shift of influenza virus pose a serious challenge for flu vaccination program. Although IFN response is known as the first important host defending mec…
Yogesh K Gupta · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · 2023 · $584,674 — ABSTRACT The massive global pandemic with high morbidity and mortality makes Severe Acute Respiratory Syndrome coronavirus-2 (SARS-CoV-2) one of the deadliest viruses in recent history. It is especially noteworthy for hijacking the normal operations of human cells. To develop effective therapies, we…
LOUISE CHANG LAURENT · GORDON RESEARCH CONFERENCES · 2023 · $10,000 — PROJECT SUMMARY This R13 application requests partial funding to support the upcoming Gordon Research Conference (GRC) on RNA Nanotechnology, which will be held in Ventura, CA on Jan 8-13, 2023, and the associated Gordon Research Symposium (GRS), to precede it on Jan 7-8. The meeting will be co-chai…
Alexander Bukreyev · UNIVERSITY OF TEXAS MED BR GALVESTON · 2023 · $766,992 — PROJECT SUMMARY/ABSTRACT The Marburg virus (MARV) and Ravn virus (RAVV), which both belong to the genus Marburgvirus of the family Filoviridae, cause the severe disease in humans, with case fatality rates up to 90%. There are no licensed vaccines against marburgviruses. Clinical trials of vaccine ca…
qing sun · TEXAS ENGINEERING EXPERIMENT STATION · 2023 · $360,295 — Among all approaches, messenger RNA (mRNA)-based vaccines have emerged as a rapid and versatile candidate to quickly respond to virus pandemics, including coronavirus disease 2019 (COVID-19). But mRNA vaccines face key potential limitations. Researchers have observed that RNA molecules tend to spont…
Sujan Shresta · LA JOLLA INSTITUTE FOR IMMUNOLOGY · 2023 · $721,849 — ABSTRACT The long-term goal of this project is to develop a dengue-Zika vaccine that provides protection against the four serotypes of dengue (DENV1-4) and Zika (ZIKV) viruses with maximal safety and efficacy. To date, flavivirus vaccine development has focused on the induction of neutralizing antib…